Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Today's call is being recorded. I would now like to turn the call over to Neda Sofarzadeh, Vice President, Head of Investor Relations, Public Relations, and Marketing. Please go ahead. Thank you, Operator. Good afternoon and welcome to ArcTera Therapeutics quarterly financial update and pipeline progress call. Today's call will be led by Joe Payne, our President and CEO, and Andy Sassine, our CFO. Dr. Pat Srivukula, our CSO and COO, will join them for the Q&A session. Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factor section in our most recent form, 10-K, and in subsequent filings with the SEC. In addition, any forward-looking statements represents our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements. And with that, I will now turn the call over to Joe. Thank you, Netta. It's good to be with you again, everybody. Over the last few months, there has been elevated interest in our mRNA therapeutics pipeline, given that we have meaningful clinical data sets forthcoming. So I will begin today's call with updates pertaining to our mRNA therapeutics pipeline. I will begin with an update on ARCT032. This i...